PRObiotics for KIdney Transplantation

NAEnrolling by invitationINTERVENTIONAL
Enrollment

132

Participants

Timeline

Start Date

November 15, 2024

Primary Completion Date

October 15, 2027

Study Completion Date

April 15, 2028

Conditions
Urinary Tract InfectionsKidney Transplant RejectionKidney Transplant InfectionDysbiosis
Interventions
DIETARY_SUPPLEMENT

OMNi-BiOTiC® 41167

The probiotic OMNi-BiOTiC® 41167 consists of 3g of 3 x 10\^9 CFU total L. gasseri W15, L. plantarum W1, L. plantarum W21, B. lactis W51, L. acidophilus W70 and L. reuteri W192 per sachet of which two are to be taken each day. Additional non-probiotic components are cranberry-extract (0.01g), D-mannose (0,4 g), vitamin D (2,25µg), maize starch and hydrolyzed rice protein. All the strains in OMNi-BiOTiC® 41167 are specifically tested and selected for their inhibition potential against the known most common uropathogens like the uropathogenic Escherichia coli (UPEC), Klebsiella pneumonia, Proteus mirabilis and Entercoccus faecalis.

DIETARY_SUPPLEMENT

Placebo

The placebo consists of all components of OMNi-BiOTiC® 41167, except the probiotic bacteria, cranberry-extract, D-mannose and vitamin D. It has the same smell, taste and texture as the OMNi-BiOTiC® 41167.

Trial Locations (1)

33100

Presidio Ospedaliero Universitario S. Maria della Misericordia, ASUFC, Udine

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Winclove Probiotics B.V.

INDUSTRY

collaborator

Institut AllergoSan

UNKNOWN

lead

University Hospital, Udine, Italy

OTHER